SENTIS™ oncology panels

816 cancer-related genes across a 1.89 Mb panel, covering actionable somatic and germline variants plus TMB, MSI, HRR and immune-checkpoint content for solid tumours.

Genes

816 genes (1.89 Mb panel)

Drugs covered

360+ therapies; 285 targeted-therapy genes

Variant types

SNV, indel, CNV, fusion

Limit of detection

1% (tissue), 0.5% (ctDNA)

Sequencing depth

1200X (tissue), ≥2700X (ctDNA)

Sample types

Fresh or biopsy tissue, FFPE section, extracted DNA, peripheral blood (control)

• 72 genes for hereditary cancer risk assessment
• 74 HRR genes for PARP-inhibitor decisions
• 32 genes linked to immune checkpoint inhibitor therapy
• UMI-based chemistry for high-accuracy variant calling

Targeted therapy guidance for non-small cell lung cancer, covering the biomarkers approved by the FDA and recommended in NCCN guidelines.

Genes

50 genes

Drugs covered

112 drugs

Variant types

SNV, indel, CNV, fusion

Limit of detection

1%

Sequencing depth

≥500X

Sample types

Fresh tissue or FFPE specimens

• CE-marked detection reagent
• Single workflow for multiple biomarkers

Guideline-aligned biomarker testing for colorectal cancer treatment selection.

Genes

23 genes

Drugs covered

55 drugs

Variant types

SNV, indel, CNV, fusion

Limit of detection

1%

Sequencing depth

≥500X

Sample types

Fresh tissue or FFPE specimens

• CE-marked detection reagent
• Cost-effective focused panel

Biomarker profiling for gastric cancer therapy decisions.

Genes

20 genes

Drugs covered

28 drugs

Variant types

SNV, indel, CNV, fusion

Limit of detection

1%

Sequencing depth

≥500X

Sample types

Fresh tissue or FFPE specimens

• CE-marked detection reagent

Gastrointestinal stromal tumour panel covering the variants that drive treatment and resistance decisions.

Genes

20 genes

Drugs covered

15 drugs

Variant types

SNV, indel, CNV, fusion

Limit of detection

1%

Sequencing depth

≥500X

Sample types

Fresh tissue or FFPE specimens

• CE-marked detection reagent